Loss of Pax3 causes reduction of melanocytes in the developing mouse cochlea
Cochlear melanocytes are intermediate cells in the stria vascularis that generate endocochlear potentials required for auditory function. Human PAX3 mutations cause Waardenburg syndrome and abnormalities of skin and retinal melanocytes, manifested as congenital hearing loss (~ 70%) and hypopigmentat...
Gespeichert in:
Veröffentlicht in: | Scientific reports 2024-01, Vol.14 (1), p.2210-11, Article 2210 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Cochlear melanocytes are intermediate cells in the stria vascularis that generate endocochlear potentials required for auditory function. Human
PAX3
mutations cause Waardenburg syndrome and abnormalities of skin and retinal melanocytes, manifested as congenital hearing loss (~ 70%) and hypopigmentation of skin, hair and eyes. However, the underlying mechanism of hearing loss remains unclear. Cochlear melanocytes in the stria vascularis originated from
Pax3
-traced melanoblasts and
Plp1
-traced Schwann cell precursors, both of which derive from neural crest cells. Here, using a
Pax3-Cre
knock-in mouse that allows lineage tracing of
Pax3
-expressing cells and disruption of
Pax3
, we found that Pax3 deficiency causes foreshortened cochlea, malformed vestibular apparatus, and neural tube defects. Lineage tracing and in situ hybridization show that
Pax3
+
derivatives contribute to S100
+
,
Kir4.1
+
and
Dct
+
melanocytes (intermediate cells) in the developing stria vascularis, all of which are significantly diminished in
Pax3
mutant animals. Taken together, these results suggest that
Pax3
is required for the development of neural crest cell-derived cochlear melanocytes, whose absence may contribute to congenital hearing loss of Waardenburg syndrome in humans. |
---|---|
ISSN: | 2045-2322 2045-2322 |
DOI: | 10.1038/s41598-024-52629-9 |